Karyopharm Therapeutics (KPTI)

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
ESG term mentions
In last year of SEC filings
AgricultureClimateClimate ChangeEnvironmentEnvironmentalForestHazardIntensityLife CycleLifecycleMaterialsNatural ResourcesNatureNuclearOffsetPackagePackagingPandemicRaw MaterialsRecyclingRegenerativeResiliencyToxicWasteAccessAffordabilityAsianAttritionBenefitsBlackCalifornia Consumer Privacy ActCharitableCharityCollective BargainingCommunityCultureCustomerCyberCybersecurityData PrivacyData SecurityDeathDemographicDisabilityDiversityDiversity and InclusionDrug PricingEmployeeEmployee EngagementEmployee RetentionEngagementEthnicGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHuman CapitalHuman ResourcesIncidentInjuriesInjuryMinorityPay for PerformancePerquisitesPrivacyProduct QualityRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkilledSkillsSocialSocietalSocietyStakeholderSupplierSupply ChainTalentTrainingUnionWomenWorkersWorkforceAnti-corruptionAssessmentAssuranceAttorneys GeneralAuditBonusBriberyChronicClassifiedClassified BoardClawbackCommitmentCommittee EvaluationConflict of InterestCorporate GovernanceCorruptionDepartment ofESGEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIndependenceIndependentInnovationInnovativeInvestigationLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityMissionOverboardingOverseeOversightPerquisitePlaintiffPledgingPoison PillPurposeQuality StandardR&DRecoupReputationReputationalReputational RiskResearch and DevelopmentResponsibilityResponsibleSelf-evaluationStrategySustainabilityTargetsTaxTax Gross UpTenureTransparencyVoting Rights
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
Karyopharm Therapeutics Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders on May 21, 2021 (the “Annual Meeting”). The following is a summary of the matters voted on at the Annual Meeting.

1.The Company’s stockholders elected Deepika Pakianathan, Ph.D., Richard Paulson, M.B.A. and Chen Schor, M.B.A., C.P.A. as Class II directors, each to serve on the board of directors of the Company for a three-year term until the 2024 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows:

Votes ForVotes WithheldBroker Non-Votes
Deepika Pakianathan, Ph.D.33,788,0867,286,49119,059,473
Richard Paulson, M.B.A.38,108,2852,966,29219,059,473
Chen Schor, M.B.A., C.P.A.38,165,0002,909,57719,059,473

2.The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement for the Annual Meeting. The results of the stockholders’ vote with respect to such approval were as follows:

Votes ForVotes AgainstVotes AbstainingBroker Non-Votes

3.The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes ForVotes AgainstVotes Abstaining